Stable and low prevalence of transmitted HIV type 1 drug resistance despite two decades of antiretroviral therapy in Hong Kong

AIDS Research and Human Retroviruses

Volumn 26, Issue 10, 2010, Pages 1079-1085

  Wong, K H ^a   Chan, W K ^a   Yam, W C ^b   Chen, J H K ^b   Alvarez Bognar, F R ^a   Chan, K C W ^a  

^a Centre for Health Protection   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; CHINESE; DRUG RESISTANCE; ETHNICITY; FEMALE; GENE MUTATION; GENETIC STRAIN; GENOTYPE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HONG KONG; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77958190999     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0272     Document Type: Article

References (30)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Murphy EL, Collier AC, Kalish LA, et al.: Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
3. Wong KH, Chan KCW, and Lee SS: Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV disease during the era of highly active antiretroviral therapy. Clin Infect Dis 2004;39:853-860.
4. Lohse N, Hansen AB, Pedersen G, et al.: Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95.
5. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al.: Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008;197:867-870.
6. Hirsch MS, Günthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47:266-285.
7. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-2426.
8. Hirsch MS, Brun-Vézinet F, Clotet B, et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-128.
9. Wong KH, Chan KC, Cheng KL, Chan WK, Kam KM, and Lee SS: Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong. AIDS Patient Care STDS 2007;21:106-115.
10. Hong Kong Advisory Council on AIDS: Construction of the first set of core indicators (2003) for monitoring Hong Kong's AIDS programmes, 2004 [http://www.info.gov. hk/aids/pdf/g136.pdf].
11. Scientific Committee on AIDS: Classification system for HIV infection and surveillance case definition for AIDS in adolescents and adults in Hong Kong. Hong Kong, 1995 [http://www.info.gov. hk/aids/pdf/g40.pdf].
12. Yam WC, Chen JH, Wong KH, et al.: Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01-AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J Clin Virol 2006;35:454-457.
13. Chen JH, Wong KH, Chan K, et al.: Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J Clin Virol 2007;39:125-131.
14. Ishizaki A, Cuong NH, Thuc PV, et al.: Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses 2009;25:175-182.
15. Kousiappa I, van de Vijver DA, Demetriades I, et al.: Genetic analysis of HIV type 1 strains from newly infected untreated patients in Cyprus: High genetic diversity and low prevalence of drug resistance. AIDS Res Hum Retroviruses 2009;25:23-35.
16. Tee KK, Kamarulzaman A, and Ng KP: Low prevalence of genotypic drug resistance mutations among antiretroviralnaive HIV type 1 patients in Malaysia. AIDS Res Hum Retroviruses 2006;22:121-124.
17. Choi JY, Kim EJ, Park YK, et al.: National survey for drugresistant variants in newly diagnosed antiretroviral drugnaive patients with HIV/AIDS in South Korea: 1999-2005. J Acquir Immune Defic Syndr 2008;49:237-242.
18. Yerly S, von Wyl V, Ledergerber B, et al.: Transmission of HIV-1 drug resistance in Switzerland: A 10-year molecular epidemiology survey. AIDS 2007;21:2223-2229.
19. Chaix ML, Descamps D, Wirden M, et al.: Stable frequency of HIV-1 transmitted drug resistance in patients at the time of transmitted infection over 1996-2006 in France. AIDS 2009;23:717-724.
20. Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192:958-966.
21. Shet A, Berry L, Mohri H, et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006;41:439-446.
22. Fong OW, Ho CF, Fung LY, et al.: Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med 2003;4:133-138.
23. Yerly S, Vora S, Rizzardi P, et al.: Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance. AIDS 2001;15:2287-2292.
24. Truong HM, Grant RM, McFarland W, et al.: Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 2006;20:2193-2197.
25. Grant RM, Hecht FM, Warmerdam M, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.
26. Bennett DE, Bertagnolio S, Sutherland D, et al.: The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008;13(Suppl 2):1-13.
27. Liu L, May S, Richman DD, et al.: Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS 2008;22:835-839.
28. Han X, Zhang M, Dai D, et al.: Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: Baseline prevalence and subtype-specific difference. AIDS Res Hum Retroviruses 2007;23:357-364.
29. SPREAD programme: Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008;22:625-635.
30. Pillay D, Green H, Matthias R, Dunn D, et al. and UK Collaborative Group on HIV Drug Resistance: Estimating HIV-1 drug resistance in antiretroviral- treated individuals in the United Kingdom. J Infect Dis 2005;192:967-973.